Telehealth Follow-up in Patients With Rheumatoid Arthritis

Sponsor
Martina Hansen's Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04536844
Collaborator
London School of Economics and Political Science (Other), Helse Sor-Ost (Other)
220
1
2
17.5
12.5

Study Details

Study Description

Brief Summary

The main objective of the present project is to test the effect of a customized Patient-Reported-Outcome (PRO)-based telehealth follow-up compared to a conventional pre-scheduled outpatient follow-up to monitor disease activity and expenses associated with the follow-up in patients with RA

Condition or Disease Intervention/Treatment Phase
  • Device: Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)
  • Other: Conventional prescheduled follow-up
N/A

Detailed Description

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with a high burden both for the patient and society. Outcomes for the individuals living with RA have been improved and the majority of RA patients are now in remission or low disease activity status. RA patients continue to be followed up by pre-scheduled visits, which may compromise accessibility for the sickest and thus, quality of care. The introduction of patient-initiated follow-up leads to a reduction in the use of outpatient clinic services without compromising outcomes. Self-monitoring and remote patient monitoring are facilitated by electronic innovative health tools. Among RA patients with low disease activity or remission, a Patient-Reported Outcome-based telehealth follow-up for tight control of disease activity in RA can achieve similar disease control as conventional outpatient follow-up and is likely to reduce the costs. Thus, the main objective of the present project is to test the effect of a customized PRO-based telehealth follow-up compared to a conventional prescheduled outpatient follow-up to monitor disease activity and expenses associated with the follow-up in Norwegian RA patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
220 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a pragmatic noninferiority randomized controlled trial (RCT) in Norwegian RA patients in clinical remission (based on RAPID3 score). The patients will be allocated to 2 groups. One group will be followed up by an electronic app, while the second group will attend conventional prescheduled visits in the outpatient clinic of Martina Hansens Hospital. A computer-generated random number sequence will be used for the randomization of the RA patients.This is a pragmatic noninferiority randomized controlled trial (RCT) in Norwegian RA patients in clinical remission (based on RAPID3 score). The patients will be allocated to 2 groups. One group will be followed up by an electronic app, while the second group will attend conventional prescheduled visits in the outpatient clinic of Martina Hansens Hospital. A computer-generated random number sequence will be used for the randomization of the RA patients.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Telehealth Follow-up in Patients With Rheumatoid Arthritis. A Noninferiority Randomized Control Trial
Actual Study Start Date :
Jun 15, 2020
Anticipated Primary Completion Date :
Aug 15, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Telehealth follow-up group

Rheumatoid arthritis patients in remission who will be followed by an electronic app

Device: Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)
An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.

Placebo Comparator: Conventional follow-up group

Rheumatoid arthritis patients in remission who will attend conventional prescheduled visits in the outpatient clinic

Other: Conventional prescheduled follow-up
Patients will be followed in the outpatient clinic by prescheduled follow-up

Outcome Measures

Primary Outcome Measures

  1. Number of patients suffering a flare [52 weeks]

    comparison of the number of patients suffering a flare in each group (Flare is defined as a routine assessment of patient index data 3 (RAPID3) score >=3)

Secondary Outcome Measures

  1. Satisfaction rates [52 weeks]

    Compare satisfaction rates (as measured by Visual analog scale (VAS) satisfaction with the follow-up procedures) among the 2 patient groups

  2. Clinical disease activity index (CDAI) [52 weeks]

    CDAI for both groups at baseline and at 52 weeks

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. 18 years

  2. Fulfilling the European League against Rheumatism (EULAR) / American College of Rheumatology (ACR) 2010 classification criteria for RA

  3. Being in remission (RAPID 3 score <=3)

  4. Able to use the electronic app

  5. Able to give informed consent

Exclusion Criteria:
  1. <18 years

  2. Severe cognitive failure

Contacts and Locations

Locations

Site City State Country Postal Code
1 Martina Hansens Hospital Sandvika Akershus Norway 1337

Sponsors and Collaborators

  • Martina Hansen's Hospital
  • London School of Economics and Political Science
  • Helse Sor-Ost

Investigators

  • Principal Investigator: Andreas Diamantopoulos, MD, PhD, MPH, Martina Hansens Hospital

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Anne Bull Haaversen, Co-principal Investigator, Martina Hansen's Hospital
ClinicalTrials.gov Identifier:
NCT04536844
Other Study ID Numbers:
  • 33172
First Posted:
Sep 3, 2020
Last Update Posted:
Oct 22, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 22, 2020